An Analysis of the Pharmaceutical Industry using Porter's Five Force model, PEST, BCG Matrix and predicting future prospects.

Many other drugs also lose patent protection leading to the creation of substitutes that are cheaper.

Although this may sound like a simple process, it is unlike how the system works at this time. Currently, patents shield drugs from imitation types for up to 20 years after the drug is developed. This does not make pharmaceutical companies happy since it can take eight years give or take after development to

2. Patent related and Generic Competition: The developed countries like US and Europe have strong patent protection laws which gives a lot of benefits for the pharmaceutical companies. But, the patent

Pharmaceutical companies also defend the costs because of the patent laws. When a patent expires, a generic drug can be made and sold for lower cost. "Although

If competitor could immediately copy a new drug the long and high cost development process would be less attractive. In order to encourage drug manufactures to have active R&D, prescription drugs are protected by patents (lasting anywhere from 10-14 years based on the contract). These patents create a monopoly for that drug and ultimately the one for the company that produces it.

Within the United States, pharmaceutical companies are protected from competition and have much power in negotiation, unlike countries with national health insurance systems who utilize delegated bodies to negotiate drug costs or reject product coverage due to disproportionately high costs (Kesselheim et al., 2016). There are two types of market protection for pharmaceutical companies: government-granted monopoly rights to their new small-molecule drug products. Pharmaceutical companies have a guaranteed period of five to seven years before the generic form can be sold, and the U.S. Patent and Trademark Office intellectual property right for patent-related exclusivity that can last up to 20 years or more (Kesselheim et al., 2016).

In the United States, both U.S. Patent Law and U.S. “ Food and Drug Administration” (FDA) law govern the exclusivity rights for new pharmaceutical products. As Chinese companies invest research time and money in developing new drugs, it is important to keep in mind both the relevant U.S. patent law and the applicable FDA law that could affect the exclusivity period for that drug in the United States. Mistakes in not obtaining proper patent coverage or satisfying the FDA laws could cost the drug company valuable exclusivity rights when that drug is sold in the United States. For a successful drug, the lost of exclusivity rights usually means the loss of substantial revenue and profit.

In this paper I will discuss Pharmaceutical Research and Manufacturers of America (PhRMA) I will talk about its purpose, scope, design, application, and how they affect the healthcare economy.

This paper will focus on the processes a pharmaceutical must take to bring a new medication to the market. It will answer the questions as to why companies should have patents on their medications and how a pharmaceutical company can recover the costs connected with failed drugs. It will look at one company that was both effective and unsuccessful in its endeavor to bring a new drug to market and explain what lead to their prosperity/disappointment.

Biopharmaceutical companies are known for their innovative discoveries but they will need to be known for their innovative business strategies to survive the Affordable Care Act. The reality of the Affordable Care Act is that physicians no longer control treatment decisions. The Affordable Care Act has been responsible for health care consolidation. Hospital mergers and hospital system formations have increased and the employment of physicians by these organizations has increased. With consolidation, the power of patient treatment has shifted from physicians to management and administration. Treatment decisions that were made by physicians are now being institutionalized. Hospital administrators, pharmacy benefit managers and insurance companies now control patient treatment decisions. Biopharmaceutical companies must understand what clinical and economic data management and administration value. There is increased focus on cost

The manufacturing of pharmaceuticals was done through druggist; they were forced to learn how to manufacture it due to the revolutionary war. After acquiring such knowledge, they were invested and these druggists were among the earliest to manufacture general chemicals in the U.S.

As part of an annual review of Pharmacorp PLC management practices, this report explores on all aspects of Pharmacorp’s managerial and business strategy by presenting an appraisal of the main risks and opportunities associated with pharmaceutical research. It will also look at the latest business models and managerial techniques to manage risks and opportunities upon the latest research and practices of change and innovation management. Other than that, this report will provide some steps and suggestions that will helpful Pharmacorp to maintain an innovative of its competitive business environment by defining the skills that Pharmacorp’s change agents or innovation managers should employ. Along with that, the use of Pharmacorp’s organisational

The pharmaceutical industry is considered to be on of the fastest growing sectors in America. The IMS Institute for Healthcare Informatics reported revenues of $424.8 billion in 2015, a 12.2 percent increase from last year (pharma commerce). Furthermore, the U.S. pharmaceutical industry is considered to be a worldwide leader with sales accounting for approximately 44.5 percent of global sales (Whiteside, 2016). The driving force of these revenue figures is Big Pharma –the largest pharmaceutical companies in the United States. In fact, Pfizer, Merck & Co., and Johnson and Johnson [J&J] are three American companies ranked at the top of the global pharmaceutical market (Dezzanni, 2016).

Moreover, generic drugs manufacturers sometimes start production of patent-protected drug analogues even before a patent expires. Although research-oriented companies in many cases are able to protect their patents, they do suffer from lost revenues.

The concept of product patent for pharmaceutical products is likely to make life saving medicine beyond the reach of the poor and deprived section of the society around the world.